

**Thyroid Cancer Drugs Market Size, Share & Trends Analysis Report By Type (Papillary Thyroid Cancer, Follicular Thyroid Cancer, Hurthle Cell Cancer, Medullary Thyroid Cancer (MTC), Anaplastic Thyroid Cancer), By Treatment (Medication, Chemotherapy, Radioactive Iodine (Radioiodine) Therapy, Hormone Therapy), By Drug Type (Thyroid Desiccated, Sorafenib, Thyrotropin Alfa, Vandetanib, Doxorubicin, Cabozantinib, Lenvatini, Sodium Iodide I-131, Dabrafenib, Trametinib, Others), By Route of Administration (Oral, Injectable, Others), By End-Users (Hospitals, Homecare, Specialty Clinics, Others) and By Region(North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2023-2031**

Market Report | 2024-01-18 | 0 pages | Straits Research

**AVAILABLE LICENSES:**

- Single User License \$4500.00
- Global Site License \$5500.00

**Report description:**

Thyroid Cancer Drugs Market Analysis and Insights

The Thyroid Cancer Drugs Market size is anticipated to reach USD 1.2 Billion in 2022 and it is projected to reach USD 4.3 Billion by 2031, growing at a CAGR of % during the forecast period.

The Global Thyroid Cancer Drugs Market Analysis report covers comprehensive data on emerging trends, market drivers, growth opportunities, and restraints that can change the market dynamics of the industry. It provides an in-depth analysis of the market segments which include types, applications, and competitor analysis.

The Global Thyroid Cancer Drugs Market growth, Size report provides a comprehensive analysis of the Pharmaceuticals industry,

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

analyzes and identifies changes in market conditions set to impact future business decisions by analyzing.

#### Research Methodology

Our research methodology constitutes a mix of secondary & primary research which ideally starts from exhaustive data mining, conducting primary interviews (suppliers/distributors/end-users), and formulating insights, estimates, growth rates accordingly. Final primary validation is a mandate to confirm our research findings with Key Opinion Leaders (KoLs), Industry Experts, Thyroid Cancer Drugs Market includes major supplies & Independent Consultants among others.

#### Global Market Scope and Thyroid Cancer Drugs Market

The scope of the report is to provide a 360-degree view of the market outlook by assessing the entire value chain and analyzing the key Thyroid Cancer Drugs Market trends from 2024 to 2032 underlying in specific geographies. Qualitative and quantitative aspects are interlinked to provide rationales on market numbers, CAGR, and forecasts.

#### Thyroid Cancer Drugs Market Country Level Analysis

The Global Thyroid Cancer Drugs Market Industry Analysis Research Report provides a basic overview of industry dominating market share expected 2024 to 2032. A detailed section on Thyroid Cancer Drugs Market share and status of critical industries is included in the report, covering, Market Segment by Regions (North America, Europe, Asia Pacific, South America and The Middle East and Africa), coverage with region wise data from 2024 to 2032.

#### Top Players in Thyroid Cancer Drugs Market

Some of the other major highlights of the demand for Thyroid Cancer Drugs Market include analysis, purchasing volume, prices, pricing analysis, and regulatory framework. Coverage on manufacturing structure, distribution channels, and Porter's Five Forces analysis are also incorporated in the scope to provide analysis on the demand and supply side. This is anticipated to create opportunities for the growth of the Thyroid Cancer Drugs Market during the forecast period.

Mylan N.V.

Bristol-Myers Squibb Company

Teva Pharmaceutical Industries Ltd

Jerome Stevens Pharmaceuticals Inc

Baxter

Abbott

Celgene Corporation

AstraZeneca

GlaxoSmithKline plc

Eisai Co. Ltd

Takeda Pharmaceutical Company Ltd

Biovista

Cytospor Therapeutics Inc

Bayer AG

Novartis AG

Bio-Path Holdings Inc.

Vascular Biogenics

#### Market Segmentation

The Global Thyroid Cancer Drugs Market Share, Demand provides the most up-to-date Pharmaceuticals industry data on the actual market situation, size, trends and future outlook. The research includes historic data from 2021 to 2023 and forecasts until 2032.

#### By Type

Papillary Thyroid Cancer

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Follicular Thyroid Cancer  
Hurthle Cell Cancer  
Medullary Thyroid Cancer (MTC)  
Anaplastic Thyroid Cancer

#### By Treatment

Medication  
Chemotherapy  
Radioactive Iodine (Radioiodine) Therapy  
Hormone Therapy

#### By Drug Type

Thyroid Desiccated  
Sorafenib  
Thyrotropin Alfa  
Vandetanib  
Doxorubicin  
Cabozantinib  
Lenvatini  
Sodium Iodide I-131  
Dabrafenib  
Trametinib  
Others

#### By Route of Administration

Oral  
Injectable  
Others

#### By End-Users

Hospitals  
Homecare  
Specialty Clinics  
Others

#### Regions Coverd

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

North America

U.S.  
Canada

Europe

U.K.  
Germany  
France  
Spain  
Italy  
Russia  
Nordic  
Benelux  
Rest of Europe

APAC

China  
Korea  
Japan  
India  
Australia  
Singapore  
Taiwan  
South East Asia  
Rest of Asia-Pacific

Middle East and Africa

UAE  
Turkey  
Saudi Arabia  
South Africa  
Egypt  
Nigeria  
Rest of MEA

LATAM

Brazil  
Mexico

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

Argentina  
Chile  
Colombia  
Rest of LATAM

#### Reasons for Doing the Study:

This report is an update of an earlier (2023) Research study. Since the previous edition of this report was published, the Public Safety and Security market has continued to evolve. In particular, the overall market growth rates forecast in the previous edition now appear to have been too high, extending the time-line for the market's development. In order to give its readers, the most up-to-date and accurate assessment of future market opportunities.

If you have any special requirements, please let us know and we will offer you the report as you want.

#### **Table of Contents:**

- 1 Executive Summary
- 2 Research Scope & Segmentation
  - 2.1 Research Objectives
  - 2.2 Limitations & Assumptions
  - 2.3 Market Scope & Segmentation
  - 2.4 Currency & Pricing Considered
- 3 Market Opportunity Assessment
  - 3.1 Emerging Regions / Countries
  - 3.2 Emerging Companies
  - 3.3 Emerging Applications / End Use
- 4 Market Trends
  - 4.1 Drivers
  - 4.2 Market Warning Factors
  - 4.3 Latest Macro Economic Indicators
  - 4.4 Geopolitical Impact
  - 4.5 Technology Factors
- 5 Market Assessment
  - 5.1 Porters Five Forces Analysis
  - 5.2 Value Chain Analysis
- 6 Global Thyroid Cancer Drugs Market Size Analysis
  - 6.1 By Type
    - 6.1.1 Papillary Thyroid Cancer
    - 6.1.2 Follicular Thyroid Cancer
    - 6.1.3 Hurthle Cell Cancer
    - 6.1.4 Medullary Thyroid Cancer (MTC)
    - 6.1.5 Anaplastic Thyroid Cancer
  - 6.2 By Treatment
    - 6.2.1 Medication
    - 6.2.2 Chemotherapy
    - 6.2.3 Radioactive Iodine (Radioiodine) Therapy
    - 6.2.4 Hormone Therapy
  - 6.3 By Drug Type

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 6.3.1 Thyroid Desiccated
- 6.3.2 Sorafenib
- 6.3.3 Thyrotropin Alfa
- 6.3.4 Vandetanib
- 6.3.5 Doxorubicin
- 6.3.6 Cabozantinib
- 6.3.7 Lenvatini
- 6.3.8 Sodium Iodide I-131
- 6.3.9 Dabrafenib
- 6.3.10 Trametinib
- 6.3.11 Others
- 6.4 By Route of Administration
  - 6.4.1 Oral
  - 6.4.2 Injectable
  - 6.4.3 Others
- 6.5 By End-Users
  - 6.5.1 Hospitals
  - 6.5.2 Homecare
  - 6.5.3 Specialty Clinics
  - 6.5.4 Others
- 7 North America Market Analysis
  - 7.1 By Type
    - 7.1.1 Papillary Thyroid Cancer
    - 7.1.2 Follicular Thyroid Cancer
    - 7.1.3 Hurthle Cell Cancer
    - 7.1.4 Medullary Thyroid Cancer (MTC)
    - 7.1.5 Anaplastic Thyroid Cancer
  - 7.2 By Treatment
    - 7.2.1 Medication
    - 7.2.2 Chemotherapy
    - 7.2.3 Radioactive Iodine (Radioiodine) Therapy
    - 7.2.4 Hormone Therapy
  - 7.3 By Drug Type
    - 7.3.1 Thyroid Desiccated
    - 7.3.2 Sorafenib
    - 7.3.3 Thyrotropin Alfa
    - 7.3.4 Vandetanib
    - 7.3.5 Doxorubicin
    - 7.3.6 Cabozantinib
    - 7.3.7 Lenvatini
    - 7.3.8 Sodium Iodide I-131
    - 7.3.9 Dabrafenib
    - 7.3.10 Trametinib
    - 7.3.11 Others
  - 7.4 By Route of Administration
    - 7.4.1 Oral
    - 7.4.2 Injectable

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 7.4.3 Others
- 7.5 By End-Users
  - 7.5.1 Hospitals
  - 7.5.2 Homecare
  - 7.5.3 Specialty Clinics
  - 7.5.4 Others
- 7.5 U.S.
- 7.6 Canada
- 8 Europe Market Analysis
  - 8.1 By Type
    - 8.1.1 Papillary Thyroid Cancer
    - 8.1.2 Follicular Thyroid Cancer
    - 8.1.3 Hurthle Cell Cancer
    - 8.1.4 Medullary Thyroid Cancer (MTC)
    - 8.1.5 Anaplastic Thyroid Cancer
  - 8.2 By Treatment
    - 8.2.1 Medication
    - 8.2.2 Chemotherapy
    - 8.2.3 Radioactive Iodine (Radioiodine) Therapy
    - 8.2.4 Hormone Therapy
  - 8.3 By Drug Type
    - 8.3.1 Thyroid Desiccated
    - 8.3.2 Sorafenib
    - 8.3.3 Thyrotropin Alfa
    - 8.3.4 Vandetanib
    - 8.3.5 Doxorubicin
    - 8.3.6 Cabozantinib
    - 8.3.7 Lenvatini
    - 8.3.8 Sodium Iodide I-131
    - 8.3.9 Dabrafenib
    - 8.3.10 Trametinib
    - 8.3.11 Others
  - 8.4 By Route of Administration
    - 8.4.1 Oral
    - 8.4.2 Injectable
    - 8.4.3 Others
  - 8.5 By End-Users
    - 8.5.1 Hospitals
    - 8.5.2 Homecare
    - 8.5.3 Specialty Clinics
    - 8.5.4 Others
  - 8.5 U.K.
  - 8.6 Germany
  - 8.7 France
  - 8.8 Spain
  - 8.9 Italy
  - 8.10 Russia

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

- 8.11 Nordic
- 8.12 Benelux
- 8.13 Rest of Europe
- 9 APAC Market Analysis
  - 9.1 By Type
    - 9.1.1 Papillary Thyroid Cancer
    - 9.1.2 Follicular Thyroid Cancer
    - 9.1.3 Hurthle Cell Cancer
    - 9.1.4 Medullary Thyroid Cancer (MTC)
    - 9.1.5 Anaplastic Thyroid Cancer
  - 9.2 By Treatment
    - 9.2.1 Medication
    - 9.2.2 Chemotherapy
    - 9.2.3 Radioactive Iodine (Radioiodine) Therapy
    - 9.2.4 Hormone Therapy
  - 9.3 By Drug Type
    - 9.3.1 Thyroid Desiccated
    - 9.3.2 Sorafenib
    - 9.3.3 Thyrotropin Alfa
    - 9.3.4 Vandetanib
    - 9.3.5 Doxorubicin
    - 9.3.6 Cabozantinib
    - 9.3.7 Lenvatini
    - 9.3.8 Sodium Iodide I-131
    - 9.3.9 Dabrafenib
    - 9.3.10 Trametinib
    - 9.3.11 Others
  - 9.4 By Route of Administration
    - 9.4.1 Oral
    - 9.4.2 Injectable
    - 9.4.3 Others
  - 9.5 By End-Users
    - 9.5.1 Hospitals
    - 9.5.2 Homecare
    - 9.5.3 Specialty Clinics
    - 9.5.4 Others
  - 9.5 China
  - 9.6 Korea
  - 9.7 Japan
  - 9.8 India
  - 9.9 Australia
  - 9.10 Singapore
  - 9.11 Taiwan
  - 9.12 South East Asia
  - 9.13 Rest of Asia-Pacific
- 10 Middle East and Africa Market Analysis
  - 10.1 By Type

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

- 10.1.1 Papillary Thyroid Cancer
- 10.1.2 Follicular Thyroid Cancer
- 10.1.3 Hurthle Cell Cancer
- 10.1.4 Medullary Thyroid Cancer (MTC)
- 10.1.5 Anaplastic Thyroid Cancer
- 10.2 By Treatment
  - 10.2.1 Medication
  - 10.2.2 Chemotherapy
  - 10.2.3 Radioactive Iodine (Radioiodine) Therapy
  - 10.2.4 Hormone Therapy
- 10.3 By Drug Type
  - 10.3.1 Thyroid Desiccated
  - 10.3.2 Sorafenib
  - 10.3.3 Thyrotropin Alfa
  - 10.3.4 Vandetanib
  - 10.3.5 Doxorubicin
  - 10.3.6 Cabozantinib
  - 10.3.7 Lenvatini
  - 10.3.8 Sodium Iodide I-131
  - 10.3.9 Dabrafenib
  - 10.3.10 Trametinib
  - 10.3.11 Others
- 10.4 By Route of Administration
  - 10.4.1 Oral
  - 10.4.2 Injectable
  - 10.4.3 Others
- 10.5 By End-Users
  - 10.5.1 Hospitals
  - 10.5.2 Homecare
  - 10.5.3 Specialty Clinics
  - 10.5.4 Others
- 10.5 UAE
- 10.6 Turkey
- 10.7 Saudi Arabia
- 10.8 South Africa
- 10.9 Egypt
- 10.10 Nigeria
- 10.11 Rest of MEA
- 11 LATAM Market Analysis
  - 11.1 By Type
    - 11.1.1 Papillary Thyroid Cancer
    - 11.1.2 Follicular Thyroid Cancer
    - 11.1.3 Hurthle Cell Cancer
    - 11.1.4 Medullary Thyroid Cancer (MTC)
    - 11.1.5 Anaplastic Thyroid Cancer
  - 11.2 By Treatment
    - 11.2.1 Medication

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

- 11.2.2 Chemotherapy
- 11.2.3 Radioactive Iodine (Radioiodine) Therapy
- 11.2.4 Hormone Therapy
- 11.3 By Drug Type
  - 11.3.1 Thyroid Desiccated
  - 11.3.2 Sorafenib
  - 11.3.3 Thyrotropin Alfa
  - 11.3.4 Vandetanib
  - 11.3.5 Doxorubicin
  - 11.3.6 Cabozantinib
  - 11.3.7 Lenvatini
  - 11.3.8 Sodium Iodide I-131
  - 11.3.9 Dabrafenib
  - 11.3.10 Trametinib
  - 11.3.11 Others
- 11.4 By Route of Administration
  - 11.4.1 Oral
  - 11.4.2 Injectable
  - 11.4.3 Others
- 11.5 By End-Users
  - 11.5.1 Hospitals
  - 11.5.2 Homecare
  - 11.5.3 Specialty Clinics
  - 11.5.4 Others
- 11.5 Brazil
- 11.6 Mexico
- 11.7 Argentina
- 11.8 Chile
- 11.9 Colombia
- 11.10 Rest of LATAM
- 12 Competitive Landscape
  - 12.1 Global Thyroid Cancer Drugs Market Share By Players
  - 12.2 M & A Agreements & Collaboration Analysis
- 13 Market Players Assessment
  - 13.1 American International Industries (GIGI)
    - 13.1.1 Overview
    - 13.1.2 Business Information
    - 13.1.3 Revenue
    - 13.1.4 ASP
    - 13.1.5 Swot Analysis
    - 13.1.6 Recent Developments
  - 13.2 &nbsp;
  - 13.3 Teva Pharmaceutical Industries Ltd&nbsp;
  - 13.4 Jerome Stevens Pharmaceuticals Inc&nbsp;
  - 13.5 Baxter&nbsp;
  - 13.6 Abbott&nbsp;
  - 13.7 Celgene Corporation&nbsp;

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 13.8 AstraZeneca&nbsp;
- 13.9 GlaxoSmithKline plc&nbsp;
- 13.10 Eisai Co. Ltd&nbsp;
- 13.11 Takeda Pharmaceutical Company Ltd
- 13.12 Biovista
- 13.13 Cytora Therapeutics Inc
- 13.14 Bayer AG&nbsp;
- 13.15 Novartis AG&nbsp;
- 13.16 Bio-Path Holdings Inc.&nbsp;
- 13.17 Vascular Biogenics&nbsp;
- 14 Research Methodology
  - 14.1 Research Data
    - 14.1.1 Secondary Data
      - 14.1.1.1 Major secondary sources
      - 14.1.1.2 Key data from secondary sources
    - 14.1.2 Primary Data
      - 14.1.2.1 Key data from primary sources
      - 14.1.2.2 Breakdown of primaries
    - 14.1.3 Secondary And Primary Research
      - 14.1.3.1 Key industry insights
  - 14.2 Market Size Estimation
    - 14.2.1 Bottom-Up Approach
    - 14.2.2 Top-Down Approach
    - 14.2.3 Market Projection
  - 14.3 Research Assumptions
    - 14.3.1 Assumptions
  - 14.4 Limitations
  - 14.5 Risk Assessment
- 15 Appendix
  - 15.1 Discussion Guide
  - 15.2 Customization Options
  - 15.3 Related Reports
- 16 Disclaimer

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

**Thyroid Cancer Drugs Market Size, Share & Trends Analysis Report By Type (Papillary Thyroid Cancer, Follicular Thyroid Cancer, Hurthle Cell Cancer, Medullary Thyroid Cancer (MTC), Anaplastic Thyroid Cancer), By Treatment (Medication, Chemotherapy, Radioactive Iodine (Radioiodine) Therapy, Hormone Therapy), By Drug Type (Thyroid Desiccated, Sorafenib, Thyrotropin Alfa, Vandetanib, Doxorubicin, Cabozantinib, Lenvatini, Sodium Iodide I-131, Dabrafenib, Trametinib, Others), By Route of Administration (Oral, Injectable, Others), By End-Users (Hospitals, Homecare, Specialty Clinics, Others) and By Region(North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2023-2031**

Market Report | 2024-01-18 | 0 pages | Straits Research

To place an Order with Scotts International:

- Print this form
- Complete the relevant blank fields and sign
- Send as a scanned email to support@scotts-international.com

**ORDER FORM:**

Select license	License	Price
	Single User License	\$4500.00
	Global Site License	\$5500.00
		VAT
		Total

\*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

\*\* VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2026-02-22"/>
		Signature	<input type="text"/>